Arbutus Biopharma Corporation ABUS Business Segments — Other segment expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept abus:OtherSegmentExpense.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's business segments — other segment expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's business segments — other segment expense?
- Arbutus Biopharma Corporation (ABUS) reported business segments — other segment expense of $237K in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — other segment expense changed year-over-year?
- Arbutus Biopharma Corporation's business segments — other segment expense decreased by 26.6% year-over-year, from $323K to $237K.
- What is the long-term trend for Arbutus Biopharma Corporation's business segments — other segment expense?
- Over 2 years (2023 to 2025), Arbutus Biopharma Corporation's business segments — other segment expense has grown at a 86.4% compound annual growth rate (CAGR), from $503K to -$1.75M.
- What does business segments — other segment expense mean?
- This category captures miscellaneous operational expenses within the segment that do not fall under specific R&D or administrative classifications. It is used to reconcile the segment's total operating costs.